Asian Stocks Rally as Cooling US Inflation Boosts Fed Rate Outlook 
Pandora Shares Rise as Q2 Results Beat Forecasts, 2026 Outlook Raised 
Goldman Sachs Eyes Investors for Nvidia’s $500 Billion AI Financing Plan 
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
Gold Prices Slip From Two-Month High as Inflation and Fed Outlook Drive Markets 
Paramount Weighs CNN Sale as $110B Warner Bros. Discovery Deal Faces Antitrust Fight 
China Automakers Accelerate Global Expansion as Domestic Car Sales Slump 
Thyssenkrupp Raises 2026 Profit Outlook as Steel and Materials Units Strengthen 
Bernstein Picks BYD and Xiaomi as Top China EV Stocks Despite Weaker Demand 
S&P 500 Retreats From Record High as AI Stocks Slide, Retail Sales Disappoint 
J.P. Morgan Upgrades SanDisk, Sets $2,250 Price Target on AI NAND Growth 
S&P 500 Hits Record High as Soft Inflation Data Eases Fed Rate Hike Fears 
Super Micro Stock Jumps 19% as AI Server Demand Drives Strong 2027 Outlook 
Trump Imposes New Tariffs on Drone Imports Over US Security Concerns 
Tesla Roadster Reveal Could Feature SpaceX Thrusters in August 
Gold Prices Rise as Weak US Retail Sales Cut Fed Rate Hike Bets 
Antofagasta Shares Drop 5% as Miner Cuts 2026 Copper Production Forecast 
Add as a preferred source on Google
Celltrion biopharmaceutical company headquartered in Incheon, South Korea, recently signed a deal with San Jose, California-based biotherapeutics company. They have teamed up to jointly carry out research and development of an oral antibody medicine.
Celltrion and Rani Therapeutics named their project RT-111 and they will work together to create the said drug with ustekinumab which is an autoimmune ingredient. As per Pulse News, the medicine is for oral treatment and mentioned that ustekinumab is being sold under the name of Stelara by Janssen Pharmaceuticals.
This is normally used for treating ulcerative colitis and Crohn’s disease. For this project, the companies will use it to develop an antibody medicine.
The US-based biotherapeutics firm has the technology to turn intravenous and subcutaneous injection-type proteins and antibody therapies into oral medicines. And under the agreement, Celltrion will be supplying its biosimilar CT-P43 referencing Stelara to Rani Therapeutic‘s clinical and non-clinical tests for RT-111.
The deal also states that the latter has a preferential right to develop and bring medicine to the global market. It was noted that ustekinumab has already been approved in the United States so it can be freely used as an ingredient in RT-111.
“We are delighted to be partnering with Celltrion, a leader in biosimilars and biologics manufacturing, on RT-111,” Rani Therapeutics’ chief executive officer, Talat Imran, said in a press release. “This agreement is a validation of our RaniPill oral drug delivery technology, which has already performed well in two separate Phase 1 trial of RT-101 and RT-102, respectively.”
The CEO added, “We value Celltrion as the exclusive provider of ustekinumab biosimilar for our RT-111 program and look forward to sharing the results of our study in due course, and potentially broadening our partnership with Celltrion.”
Celltrion’s head of medical science unit, Kim Sung Hyun, also commented on its new partnership deal with Rani by saying, “Celltrion strives to address unmet needs of patients and partnering with Rani offers the opportunity to replace painful injections with a pill.”
